Ajay Nirula

Rheumatology

5171 Meadows Del Mar
San Diego, CA 92130

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Spatial profiling of giant cell arteritis tissues reveals immune heterogeneity and potential predictors of glucocorticoid response.

Spatial profiling of giant cell arteritis tissues reveals immune heterogeneity and potential predictors of glucocorticoid response.

Journal: Annals of the rheumatic diseases

Published: February 05, 2025

A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa.

A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa.

Journal: Journal of the American Academy of Dermatology

Published: December 06, 2024

The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.

The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.

Journal: Nature communications

Published: May 16, 2024

Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19.

Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19.

Journal: Infectious diseases and therapy

Published: May 13, 2024

Serum IL-6 and PTX3 predict severe outcome from COVID-19 in ambulatory subjects: Impact for future therapeutic decisions.

Serum IL-6 and PTX3 predict severe outcome from COVID-19 in ambulatory subjects: Impact for future therapeutic decisions.

Journal: PloS one

Published: May 10, 2024

Systematic literature review on early clinical evidence for immune-resolution therapies and potential benefits to patients and healthcare providers.

Systematic literature review on early clinical evidence for immune-resolution therapies and potential benefits to patients and healthcare providers.

Journal: Frontiers in immunology

Published: April 29, 2024

Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study.

Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study.

Journal: Nature communications

Published: November 06, 2023

Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis. Reply.

Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis. Reply.

Journal: The New England journal of medicine

Published: July 26, 2023

A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis.

A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis.

Journal: The New England journal of medicine

Published: May 17, 2023

Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.

Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.

Journal: Nature communications

Published: January 19, 2023

The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination.

The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination.

Journal: Science translational medicine

Published: June 09, 2022

COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine.

COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine.

Journal: PloS one

Published: May 11, 2022

Showing 1-12 of 45

Last Updated: 09/26/2026